<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831103</url>
  </required_header>
  <id_info>
    <org_study_id>EPB348-0201</org_study_id>
    <nct_id>NCT00831103</nct_id>
  </id_info>
  <brief_title>A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multi-center, Parallel-group Dose-ranging Study Assessing the Safety and Efficacy of EPB-348 Versus Valacyclovir Among Immunocompetent Patients With an Acute Episode of Herpes Zoster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epiphany Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epiphany Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics and dosage of EPB-348 that
      best balances safety and efficacy among adult immunocompetent patients with an acute episode
      of herpes zoster.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In cells infected with varicella-zoster virus, there is evidence to suggest that EPB-348
      could offer clinically important advantages in the treatment of acute herpes zoster over
      currently available therapies due to rapid absorption and conversion to the active moiety as
      well as a longer intra-cellular half-life in infected cells. Clinically, these
      characteristics could translate into once-daily dosing versus thrice-daily dosing as seen
      with current therapy, leading to a higher rate of compliance and quality-of-life, especially
      among elderly patients. The objective of EPB348-0201 is to determine the pharmacokinetics and
      dosage of EPB-348 that best balances safety and efficacy among adult immunocompetent patients
      with an acute episode of herpes zoster. This multi-center study will randomly assign patients
      to either EPB-348 1000 mg once daily or EPB-348 2000 mg once daily or valacyclovir 1000 mg
      three times daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the time-to-crusting of vesicles on patients in each of the EPB-348 dosing arms versus the valacyclovir dosing arm.</measure>
    <time_frame>Daily assessment during the seven days of treament then weekly until Day 28</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">373</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>EPB-348 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPB-348 1000 mg dosed once daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPB-348 2000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPB-348 2000 mg dosed once daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPB-348 3000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPB-348 3000 mg dosed once daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valacyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valacyclovir 1000 mg dosed three times daily for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPB-348</intervention_name>
    <description>Treated over seven days</description>
    <arm_group_label>EPB-348 1000 mg</arm_group_label>
    <arm_group_label>EPB-348 2000 mg</arm_group_label>
    <arm_group_label>EPB-348 3000 mg</arm_group_label>
    <other_name>Valomaciclovir Stearate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>Treated over seven days</description>
    <arm_group_label>Valacyclovir</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults at least 18 years of age

          -  Patients with signs and symptoms consistent with acute herpes zoster disease, namely,
             a dermatomal vesicular rash which may be preceded by pain and parasthesias in the days
             before vesicular eruption

          -  Herpes Zoster associated rash present for â‰¤ 72 hours

          -  Patients who are deemed to be immunocompetent based on history and physical exam

        Exclusion Criteria:

          -  Females who are pregnant or nursing

          -  History or clinical manifestations of significant metabolic, hematological, pulmonary,
             ischemic, or unstable heart disease, gastrointestinal, neurological, psychiatric,
             renal, urological, endocrine, opthalmologic, or immune mediated disease including HIV
             or HBsAg positivity

          -  Chronic genital herpes

          -  Patients who received cytotoxic or immunosuppressive drug therapy within 3 months
             prior to study participation

          -  Previous vaccinations against Herpes Zoster

          -  Patients with &gt; 50% of vesicles crusted at screen

          -  Patients who received topical or systemic antiviral medications or immunomodulatory
             agents for herpes zoster viral infections or capsaicin within 4 weeks of study
             participation

          -  Patients with a history of congenital, acquired, or corticosteroid induced
             immunodeficiency, including malignancy, significantly impaired renal function
             (creatinine clearance &lt; 50 cc/min), and impaired hepatic function (ALT or AST levels &gt;
             3 times the upper limit of normal)

          -  QTc &gt; 500msec

          -  Patients with a history of intolerance or hypersensitivity to acyclovir, penciclovir,
             valacyclovir, or famciclovir

          -  Patients with gastrointestinal dysfunction that might interfere with drug absorption

          -  Patients, considered by the investigator, for any reason, to be an unsuitable
             candidate for receiving the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen K Tyring, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center, Houston, Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical Studies-Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, Wise JM, Martin PA; Valomaciclovir Zoster Study Group. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol. 2012 Aug;84(8):1224-32. doi: 10.1002/jmv.23329.</citation>
    <PMID>22711350</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EPB348</keyword>
  <keyword>Valomaciclovir Stearate</keyword>
  <keyword>Valacyclovir</keyword>
  <keyword>Herpes Zoster</keyword>
  <keyword>Shingles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

